Perceptronix Medical Inc., an independent quantitative cytology laboratory specializing in early cancer detection tests, will be exhibiting at the Toronto Academy of Dentistry’s 71st Annual Winter Clinic on November 14, 2008 at the Metro Toronto Convention Centre. Perceptronix will be showcasing OralAdvance(TM), a new quantitative cytology test for the early detection of oral cancer, and demonstrating its use at booth 1112.
With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance(TM), with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions when biopsy is not warranted or possible. It provides an objective measure of gross DNA abnormality that can give additional information about the pre-malignant or malignant nature of a lesion.
About Perceptronix Medical Inc.
Perceptronix Medical Inc. (Vancouver, Canada) is a private laboratory and cancer diagnostics company specializing in the provision of innovative early cancer detection tests based on quantitative cytology. The Company’s DNA image cytometry technology was developed in partnership with the British Columbia Cancer Agency (Vancouver, Canada). Quantitative cytology provides physicians with an innovative cytopathology assessment based on an objective measure of large-scale DNA abnormality that can indicate precancerous or cancerous changes. In addition to general quantitative cytology services, the company has developed innovative tests for the early detection of lung cancer and oral cancer.
Contacts: Perceptronix Medical Inc. Alexei Doudkine, PhD Director of Business Development (604) 629-8785 Email: [email protected]
SOURCE: Perceptronix Medical Inc.
Comments